Skip to main content
Erschienen in: Journal of General Internal Medicine 7/2010

01.07.2010 | Original Research

Primary Care of the Renal Transplant Patient

verfasst von: Gaurav Gupta, MD, Mark L. Unruh, MD, Thomas D. Nolin, PharmD, PhD, Peggy B. Hasley, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

There has been a remarkable rise in the number of kidney transplant recipients (KTR) in the US over the last decade. Increasing use of potent immunosuppressants, which are also potentially diabetogenic and atherogenic, can result in worsening of pre-existing medical conditions as well as development of post-transplant disease. This, coupled with improving long-term survival, is putting tremendous pressure on transplant centers that were not designed to deliver primary care to KTR. Thus, increasing numbers of KTR will present to their primary care physicians (PCP) post-transplant for routine medical care. Similar to native chronic kidney disease patients, KTRs are vulnerable to cardiovascular disease as well as a host of other problems including bone disease, infections and malignancies. Deaths related to complications of cardiovascular disease and malignancies account for 60–65% of long-term mortality among KTRs. Guidelines from the National Kidney Foundation and the European Best Practice Guidelines Expert Group on the management of hypertension, dyslipidemia, smoking, diabetes and bone disease should be incorporated into the long-term care plan of the KTR to improve outcomes. A number of transplant centers do not supply PCPs with protocols and guidelines, making the task of the PCP more difficult. Despite this, PCPs are expected to continue to provide general preventive medicine, vaccinations and management of chronic medical problems. In this narrative review, we examine the common medical problems seen in KTR from the PCP’s perspective. Medical management issues related to immunosuppressive medications are also briefly discussed.
Literatur
1.
2.
Zurück zum Zitat Organ Procurement and Transplant Network/Scientific Registry of Transplant Recipients Annual Report. 2007 Donation and transplantation trends. accessed in March 2009 from www.unos.org. Organ Procurement and Transplant Network/Scientific Registry of Transplant Recipients Annual Report. 2007 Donation and transplantation trends. accessed in March 2009 from www.​unos.​org.
3.
Zurück zum Zitat Cecka JM. The OPTN/UNOS Renal Transplant Registry. Clin Transpl. 2005:1-16 Cecka JM. The OPTN/UNOS Renal Transplant Registry. Clin Transpl. 2005:1-16
4.
Zurück zum Zitat Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis. 2007;49(1 Suppl 1):A6–7–S1–296. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis. 2007;49(1 Suppl 1):A6–7–S1–296.
5.
Zurück zum Zitat Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605–12.PubMedCrossRef Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605–12.PubMedCrossRef
6.
Zurück zum Zitat McCashland TM. Posttransplantation care: role of the primary care physician versus transplant center. Liver Transpl. 2001;7(11 Suppl 1):S2–S12.PubMedCrossRef McCashland TM. Posttransplantation care: role of the primary care physician versus transplant center. Liver Transpl. 2001;7(11 Suppl 1):S2–S12.PubMedCrossRef
7.
Zurück zum Zitat Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-year follow-up. Clin Transplant. 2004;18(5):596–604.PubMedCrossRef Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-year follow-up. Clin Transplant. 2004;18(5):596–604.PubMedCrossRef
8.
Zurück zum Zitat Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16–S23.PubMed Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16–S23.PubMed
9.
Zurück zum Zitat Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant. 1999;14(3):648–54.PubMedCrossRef Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant. 1999;14(3):648–54.PubMedCrossRef
10.
Zurück zum Zitat Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis. 2005;46(4):720–33.PubMedCrossRef Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis. 2005;46(4):720–33.PubMedCrossRef
11.
Zurück zum Zitat Abbott KC, Hypolite IO, Hshieh P, Cruess D, Taylor AJ, Agodoa LY. Hospitalized congestive heart failure after renal transplantation in the United States. Ann Epidemiol. 2002;12(2):115–22.PubMedCrossRef Abbott KC, Hypolite IO, Hshieh P, Cruess D, Taylor AJ, Agodoa LY. Hospitalized congestive heart failure after renal transplantation in the United States. Ann Epidemiol. 2002;12(2):115–22.PubMedCrossRef
12.
Zurück zum Zitat Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol. 2006;17(3):900–7.PubMedCrossRef Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol. 2006;17(3):900–7.PubMedCrossRef
13.
Zurück zum Zitat Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006;82(5):603–11.PubMedCrossRef Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006;82(5):603–11.PubMedCrossRef
14.
Zurück zum Zitat Marcen R. Cardiovascular risk factors in renal transplantation-current controversies. Nephrol Dial Transplant. 2006;21:(Suppl 3):iii3–8PubMedCrossRef Marcen R. Cardiovascular risk factors in renal transplantation-current controversies. Nephrol Dial Transplant. 2006;21:(Suppl 3):iii3–8PubMedCrossRef
15.
Zurück zum Zitat Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11(9):1735–43.PubMed Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11(9):1735–43.PubMed
16.
Zurück zum Zitat Ducloux D, Ruedin C, Gibey R, et al. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant. 1998;13(11):2890–3.PubMedCrossRef Ducloux D, Ruedin C, Gibey R, et al. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant. 1998;13(11):2890–3.PubMedCrossRef
17.
Zurück zum Zitat Varagunam M, Finney H, Trevitt R, et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis. 2004;43(3):502–7.PubMedCrossRef Varagunam M, Finney H, Trevitt R, et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis. 2004;43(3):502–7.PubMedCrossRef
18.
Zurück zum Zitat Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation. 2002;73(8):1345–8.PubMedCrossRef Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation. 2002;73(8):1345–8.PubMedCrossRef
19.
Zurück zum Zitat Lentine KL, Rocca-Rey LA. Bacchi G, et al. Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review. Transplantation. 2008;86(2):303–12. Lentine KL, Rocca-Rey LA. Bacchi G, et al. Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review. Transplantation. 2008;86(2):303–12.
20.
Zurück zum Zitat Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003;41(2):480–7.PubMedCrossRef Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003;41(2):480–7.PubMedCrossRef
21.
Zurück zum Zitat Baum CL, Thielke K, Westin E, Kogan E, Cicalese L, Benedetti E. Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients. Nutrition. 2002;18(2):139–46.PubMedCrossRef Baum CL, Thielke K, Westin E, Kogan E, Cicalese L, Benedetti E. Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients. Nutrition. 2002;18(2):139–46.PubMedCrossRef
22.
Zurück zum Zitat Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. American J Transplantation. 2005;5(11):2710–8.CrossRef Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. American J Transplantation. 2005;5(11):2710–8.CrossRef
23.
Zurück zum Zitat Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation. 2006;82(12):1673–6.PubMedCrossRef Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation. 2006;82(12):1673–6.PubMedCrossRef
24.
Zurück zum Zitat Modlin CS, Flechner SM, Goormastic M, et al. Should obese patients lose weight before receiving a kidney transplant? Transplantation. 1997;64(4):599–604.PubMedCrossRef Modlin CS, Flechner SM, Goormastic M, et al. Should obese patients lose weight before receiving a kidney transplant? Transplantation. 1997;64(4):599–604.PubMedCrossRef
25.
Zurück zum Zitat Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6(2):357–63.PubMedCrossRef Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6(2):357–63.PubMedCrossRef
26.
Zurück zum Zitat Jindal RM, Zawada ET Jr. Obesity and kidney transplantation. Am J Kidney Dis. 2004;43(6):943–52.PubMedCrossRef Jindal RM, Zawada ET Jr. Obesity and kidney transplantation. Am J Kidney Dis. 2004;43(6):943–52.PubMedCrossRef
27.
Zurück zum Zitat Lopes IM, Martin M, Errasti P, Martinez JA. Benefits of a dietary intervention on weight loss, body composition, and lipid profile after renal transplantation. Nutrition. 1999;15(1):7–10.PubMedCrossRef Lopes IM, Martin M, Errasti P, Martinez JA. Benefits of a dietary intervention on weight loss, body composition, and lipid profile after renal transplantation. Nutrition. 1999;15(1):7–10.PubMedCrossRef
28.
Zurück zum Zitat Painter PL, Hector L, Ray K, et al. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. Am J Kidney Dis. 2003;42(2):362–9.PubMedCrossRef Painter PL, Hector L, Ray K, et al. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. Am J Kidney Dis. 2003;42(2):362–9.PubMedCrossRef
29.
Zurück zum Zitat Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–46.PubMed Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–46.PubMed
30.
Zurück zum Zitat Barbaro D, Orsini P, Pallini S, Piazza F, Pasquini C. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract. Mar-Apr. 2002;8(2):124–6. Barbaro D, Orsini P, Pallini S, Piazza F, Pasquini C. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract. Mar-Apr. 2002;8(2):124–6.
31.
Zurück zum Zitat Modanlou KA, Muthyala U, Xiao H, et al. Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation. 2009;87(8):1167–73.PubMedCrossRef Modanlou KA, Muthyala U, Xiao H, et al. Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation. 2009;87(8):1167–73.PubMedCrossRef
32.
Zurück zum Zitat Alexander JW, Goodman H. Gastric bypass in chronic renal failure and renal transplant. Nutr Clin Pract. 2007;22(1):16–21.PubMedCrossRef Alexander JW, Goodman H. Gastric bypass in chronic renal failure and renal transplant. Nutr Clin Pract. 2007;22(1):16–21.PubMedCrossRef
33.
Zurück zum Zitat Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clinical Transplantation. May-Jun. 2008;22(3):281–91. Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clinical Transplantation. May-Jun. 2008;22(3):281–91.
34.
Zurück zum Zitat Ablassmaier B, Klaua S, Jacobi CA, Muller JM. Laparoscopic gastric banding after heart transplantation. Obes Surg. 2002;12(3):412–5.PubMedCrossRef Ablassmaier B, Klaua S, Jacobi CA, Muller JM. Laparoscopic gastric banding after heart transplantation. Obes Surg. 2002;12(3):412–5.PubMedCrossRef
35.
Zurück zum Zitat Koshy AN, Coombes JS, Wilkinson S, Fassett RG. Laparoscopic gastric banding surgery performed in obese dialysis patients prior to kidney transplantation. Am J Kidney Dis. 2008;52(4):e15–7.PubMedCrossRef Koshy AN, Coombes JS, Wilkinson S, Fassett RG. Laparoscopic gastric banding surgery performed in obese dialysis patients prior to kidney transplantation. Am J Kidney Dis. 2008;52(4):e15–7.PubMedCrossRef
36.
Zurück zum Zitat Weiss H, Nehoda H, Labeck B, Oberwalder M, Konigsrainer A, Margreiter R. Organ transplantation and obesity: evaluation, risks and benefits of therapeutic strategies. Obes Surg. 2000;10(5):465–9.PubMedCrossRef Weiss H, Nehoda H, Labeck B, Oberwalder M, Konigsrainer A, Margreiter R. Organ transplantation and obesity: evaluation, risks and benefits of therapeutic strategies. Obes Surg. 2000;10(5):465–9.PubMedCrossRef
37.
Zurück zum Zitat Buch KE, El-Sabrout R, Butt KM. Complications of laparoscopic gastric banding in renal transplant recipients: a case study. Transplant Proc. 2006;38(9):3109–11.PubMedCrossRef Buch KE, El-Sabrout R, Butt KM. Complications of laparoscopic gastric banding in renal transplant recipients: a case study. Transplant Proc. 2006;38(9):3109–11.PubMedCrossRef
38.
Zurück zum Zitat Olarte IG, Hawasli A. Kidney transplant complications and obesity. Am J Surg. 2009;197(3):424–6.PubMedCrossRef Olarte IG, Hawasli A. Kidney transplant complications and obesity. Am J Surg. 2009;197(3):424–6.PubMedCrossRef
39.
Zurück zum Zitat Duffey BG, Pedro RN, Makhlouf A, et al. Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis. J Am Coll Surg. 2008;206(3):1145–53.PubMedCrossRef Duffey BG, Pedro RN, Makhlouf A, et al. Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis. J Am Coll Surg. 2008;206(3):1145–53.PubMedCrossRef
40.
Zurück zum Zitat Lieske JC, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol. 2008;28(2):163–73.PubMedCrossRef Lieske JC, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol. 2008;28(2):163–73.PubMedCrossRef
41.
Zurück zum Zitat Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 2007;72(1):100–7.PubMedCrossRef Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 2007;72(1):100–7.PubMedCrossRef
42.
Zurück zum Zitat Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol. 2000;11(4):753–9.PubMed Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol. 2000;11(4):753–9.PubMed
43.
Zurück zum Zitat Sung RS, Althoen M, Howell TA, Ojo AO, Merion RM. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation. 2001;71(12):1752–7.PubMedCrossRef Sung RS, Althoen M, Howell TA, Ojo AO, Merion RM. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation. 2001;71(12):1752–7.PubMedCrossRef
44.
Zurück zum Zitat Banas MC, Banas B, Wolf J, et al. Smoking behaviour of patients before and after renal transplantation. Nephrol Dial Transplant. 2008;23(4):1442–6.PubMedCrossRef Banas MC, Banas B, Wolf J, et al. Smoking behaviour of patients before and after renal transplantation. Nephrol Dial Transplant. 2008;23(4):1442–6.PubMedCrossRef
45.
Zurück zum Zitat Strategies for reducing exposure to environmental tobacco smoke, increasing tobacco-use cessation, and reducing initiation in communities and health-care systems. A report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm Rep. Nov 10 2000;49(RR-12):1–11. Strategies for reducing exposure to environmental tobacco smoke, increasing tobacco-use cessation, and reducing initiation in communities and health-care systems. A report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm Rep. Nov 10 2000;49(RR-12):1–11.
46.
Zurück zum Zitat Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146.
47.
Zurück zum Zitat Lewis BR, Aoun SL, Bernstein GA, Crow SJ. Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate. J Child Adolesc Psychopharmacol. Summer. 2001;11(2):193–8.CrossRef Lewis BR, Aoun SL, Bernstein GA, Crow SJ. Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate. J Child Adolesc Psychopharmacol. Summer. 2001;11(2):193–8.CrossRef
48.
Zurück zum Zitat Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56–63.PubMedCrossRef Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56–63.PubMedCrossRef
49.
Zurück zum Zitat Shirali AC, Bia MJ. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol. 2008;3(2):491–504.PubMedCrossRef Shirali AC, Bia MJ. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol. 2008;3(2):491–504.PubMedCrossRef
50.
Zurück zum Zitat McIntyre RS. Varenicline and suicidality: a new era in medication safety surveillance. Expert Opin Drug Saf. 2008;7(5):511–4.PubMedCrossRef McIntyre RS. Varenicline and suicidality: a new era in medication safety surveillance. Expert Opin Drug Saf. 2008;7(5):511–4.PubMedCrossRef
51.
Zurück zum Zitat McClure JB, Swan GE, Jack L, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med. 2009;24(5):563–9.PubMedCrossRef McClure JB, Swan GE, Jack L, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med. 2009;24(5):563–9.PubMedCrossRef
52.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure—The JNC 7 Report. JAMA. 2003;289(19):2560–72.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure—The JNC 7 Report. JAMA. 2003;289(19):2560–72.PubMedCrossRef
53.
Zurück zum Zitat Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43(6):1071–81.PubMedCrossRef Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43(6):1071–81.PubMedCrossRef
54.
Zurück zum Zitat Curtis JJ. Cyclosporine and Posttransplant Hypertension. J Am Soc Nephrol. 1992;2(12):S243–5.PubMed Curtis JJ. Cyclosporine and Posttransplant Hypertension. J Am Soc Nephrol. 1992;2(12):S243–5.PubMed
55.
Zurück zum Zitat Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999;33(5):829–39.PubMedCrossRef Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999;33(5):829–39.PubMedCrossRef
56.
Zurück zum Zitat Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA. 2000;283(5):633–8.PubMedCrossRef Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA. 2000;283(5):633–8.PubMedCrossRef
57.
Zurück zum Zitat Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. Jan. 1998;53(1):217–22.CrossRef Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. Jan. 1998;53(1):217–22.CrossRef
58.
Zurück zum Zitat K/DOQI. clinical practice guidelines on hypertension and anti hypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5):S14–S290. K/DOQI. clinical practice guidelines on hypertension and anti hypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5):S14–S290.
59.
Zurück zum Zitat European best practice guidelines for renal transplantation (2002) Section IV: Long-term management of the transplant recipient. IV.5.1. Cardiovascular risks. Cardiovascular disease after renal transplantation. Nephrol Dial Transplant. 17 Suppl 4:24–5. European best practice guidelines for renal transplantation (2002) Section IV: Long-term management of the transplant recipient. IV.5.1. Cardiovascular risks. Cardiovascular disease after renal transplantation. Nephrol Dial Transplant. 17 Suppl 4:24–5.
60.
Zurück zum Zitat Tomson CR. Ambulatory blood pressure measurement in kidney transplantation: an overview. Transplantation. 2003;76(11):1643–4.PubMedCrossRef Tomson CR. Ambulatory blood pressure measurement in kidney transplantation: an overview. Transplantation. 2003;76(11):1643–4.PubMedCrossRef
61.
Zurück zum Zitat Kooman JP, Christiaans MH, Boots JM, van Der Sande FM, Leunissen KM, van Hooff JP. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. Am J Kidney Dis. 2001;37(6):1170–6.PubMedCrossRef Kooman JP, Christiaans MH, Boots JM, van Der Sande FM, Leunissen KM, van Hooff JP. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. Am J Kidney Dis. 2001;37(6):1170–6.PubMedCrossRef
62.
Zurück zum Zitat Lipkin GW, Tucker B, Giles M, Raine AE. Ambulatory blood pressure and left ventricular mass in cyclosporin-and non-cyclosporin-treated renal transplant recipients. J Hypertens. 1993;11(4):439–42.PubMedCrossRef Lipkin GW, Tucker B, Giles M, Raine AE. Ambulatory blood pressure and left ventricular mass in cyclosporin-and non-cyclosporin-treated renal transplant recipients. J Hypertens. 1993;11(4):439–42.PubMedCrossRef
63.
Zurück zum Zitat Covic A, Segall L, Goldsmith DJ. Ambulatory blood pressure monitoring in renal transplantation: should ABPM be routinely performed in renal transplant patients? Transplantation. 2003;76(11):1640–2.PubMedCrossRef Covic A, Segall L, Goldsmith DJ. Ambulatory blood pressure monitoring in renal transplantation: should ABPM be routinely performed in renal transplant patients? Transplantation. 2003;76(11):1640–2.PubMedCrossRef
64.
Zurück zum Zitat Premasathian NC, Muehrer R, Brazy PC, Pirsch JD, Becker BN. Blood pressure control in kidney transplantation: therapeutic implications. J Hum Hypertens. 2004;18(12):871–7.PubMedCrossRef Premasathian NC, Muehrer R, Brazy PC, Pirsch JD, Becker BN. Blood pressure control in kidney transplantation: therapeutic implications. J Hum Hypertens. 2004;18(12):871–7.PubMedCrossRef
65.
Zurück zum Zitat Olyaei AJ, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs. 1999;58(6):1011–27.PubMedCrossRef Olyaei AJ, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs. 1999;58(6):1011–27.PubMedCrossRef
66.
Zurück zum Zitat Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation. 2009;9(s3):S1–55. Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation. 2009;9(s3):S1–55.
67.
Zurück zum Zitat KDOQI. Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–54. KDOQI. Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–54.
68.
Zurück zum Zitat Midtvedt K, Hartmann A, Holdaas H, Fauchald P. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial. Clin Transplant. 2001;15(6):426–31.PubMedCrossRef Midtvedt K, Hartmann A, Holdaas H, Fauchald P. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial. Clin Transplant. 2001;15(6):426–31.PubMedCrossRef
69.
Zurück zum Zitat Ladefoged SD, Andersen CB. Calcium channel blockers in kidney transplantation. Clin Transplant. 1994;8(2 Pt 1):128–33.PubMed Ladefoged SD, Andersen CB. Calcium channel blockers in kidney transplantation. Clin Transplant. 1994;8(2 Pt 1):128–33.PubMed
70.
Zurück zum Zitat European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. Nephrol Dial Transplant. 2002;17(Suppl 4):1–67. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. Nephrol Dial Transplant. 2002;17(Suppl 4):1–67.
71.
Zurück zum Zitat Kothari J, Nash M, Zaltzman J, Ramesh, Prasad GV. Diltiazem use in tacrolimus-treated renal transplant recipients. J Clin Pharm Ther. Oct. 2004;29(5):425–30.CrossRef Kothari J, Nash M, Zaltzman J, Ramesh, Prasad GV. Diltiazem use in tacrolimus-treated renal transplant recipients. J Clin Pharm Ther. Oct. 2004;29(5):425–30.CrossRef
72.
Zurück zum Zitat Djamali A, Samaniego M, Muth B, et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol. 2006;1(4):623–40.PubMedCrossRef Djamali A, Samaniego M, Muth B, et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol. 2006;1(4):623–40.PubMedCrossRef
73.
Zurück zum Zitat Buturovic-Ponikvar J. Renal transplant artery stenosis. Nephrol Dial Transplant. 2003;18(Suppl 5):v74–7.PubMedCrossRef Buturovic-Ponikvar J. Renal transplant artery stenosis. Nephrol Dial Transplant. 2003;18(Suppl 5):v74–7.PubMedCrossRef
74.
Zurück zum Zitat Valpreda S, Messina M, Rabbia C. Stenting of transplant renal artery stenosis: outcome in a single center study. J Cardiovasc Surg (Torino). 2008;49(5):565–70. Valpreda S, Messina M, Rabbia C. Stenting of transplant renal artery stenosis: outcome in a single center study. J Cardiovasc Surg (Torino). 2008;49(5):565–70.
75.
Zurück zum Zitat Voiculescu A, Hollenbeck M, Plum J, et al. Iliac artery stenosis proximal to a kidney transplant: clinical findings, duplex-sonographic criteria, treatment, and outcome. Transplantation. 2003;76(2):332–9.PubMedCrossRef Voiculescu A, Hollenbeck M, Plum J, et al. Iliac artery stenosis proximal to a kidney transplant: clinical findings, duplex-sonographic criteria, treatment, and outcome. Transplantation. 2003;76(2):332–9.PubMedCrossRef
76.
Zurück zum Zitat Voiculescu A, Schmitz M, Hollenbeck M, et al. Management of arterial stenosis affecting kidney graft perfusion: a single-centre study in 53 patients. Am J Transplant. 2005;5(7):1731–8.PubMedCrossRef Voiculescu A, Schmitz M, Hollenbeck M, et al. Management of arterial stenosis affecting kidney graft perfusion: a single-centre study in 53 patients. Am J Transplant. 2005;5(7):1731–8.PubMedCrossRef
77.
Zurück zum Zitat Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4:13–53.PubMedCrossRef Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4:13–53.PubMedCrossRef
78.
Zurück zum Zitat Chueh SCJ, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. Transplantation. 2003;76(2):375–82.PubMedCrossRef Chueh SCJ, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. Transplantation. 2003;76(2):375–82.PubMedCrossRef
79.
Zurück zum Zitat Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63(3):331–8.PubMedCrossRef Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63(3):331–8.PubMedCrossRef
80.
Zurück zum Zitat Legendre C, Campistol JM, Squifflet JP, Burke JT. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc. 2003;35(3 Suppl):151S–3S.PubMedCrossRef Legendre C, Campistol JM, Squifflet JP, Burke JT. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc. 2003;35(3 Suppl):151S–3S.PubMedCrossRef
81.
Zurück zum Zitat Fellstrom B. Risk factors for and management of post-transplantation cardiovascular disease. BioDrugs. 2001;15(4):261–78.PubMedCrossRef Fellstrom B. Risk factors for and management of post-transplantation cardiovascular disease. BioDrugs. 2001;15(4):261–78.PubMedCrossRef
82.
Zurück zum Zitat Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation. 1998;65(9):1272–4.PubMedCrossRef Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation. 1998;65(9):1272–4.PubMedCrossRef
83.
Zurück zum Zitat Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988;84(6):985–92.PubMedCrossRef Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988;84(6):985–92.PubMedCrossRef
84.
Zurück zum Zitat Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
85.
Zurück zum Zitat Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–31.PubMedCrossRef Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–31.PubMedCrossRef
86.
Zurück zum Zitat Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs. 2003;63(4):367–78.PubMedCrossRef Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs. 2003;63(4):367–78.PubMedCrossRef
87.
Zurück zum Zitat Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant. 2005;5(9):2236–43.PubMedCrossRef Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant. 2005;5(9):2236–43.PubMedCrossRef
88.
Zurück zum Zitat Nogueira J, Weir M. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. Clin J Am Soc Nephrol. 2007;2(4):766–85.PubMedCrossRef Nogueira J, Weir M. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. Clin J Am Soc Nephrol. 2007;2(4):766–85.PubMedCrossRef
89.
Zurück zum Zitat Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43.PubMedCrossRef Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43.PubMedCrossRef
90.
Zurück zum Zitat Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation. 2006;81(5):804–7.PubMedCrossRef Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation. 2006;81(5):804–7.PubMedCrossRef
91.
Zurück zum Zitat Lim AK, Manley KJ, Roberts MA, Fraenkel MB. Fish oil treatment for kidney transplant recipients: a meta-analysis of randomized controlled trials. Transplantation. 2007;83(7):831–8.PubMedCrossRef Lim AK, Manley KJ, Roberts MA, Fraenkel MB. Fish oil treatment for kidney transplant recipients: a meta-analysis of randomized controlled trials. Transplantation. 2007;83(7):831–8.PubMedCrossRef
92.
Zurück zum Zitat Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553–64.PubMedCrossRef Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553–64.PubMedCrossRef
93.
Zurück zum Zitat Celik S, Doesch A, Erbel C, et al. Beneficial effect of omega-3 fatty acids on sirolimus-or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation. 2008;86(2):245–50.PubMedCrossRef Celik S, Doesch A, Erbel C, et al. Beneficial effect of omega-3 fatty acids on sirolimus-or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation. 2008;86(2):245–50.PubMedCrossRef
94.
Zurück zum Zitat Kasiske BL. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant. 2005;5(6):1576.PubMedCrossRef Kasiske BL. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant. 2005;5(6):1576.PubMedCrossRef
95.
Zurück zum Zitat Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178–85.PubMedCrossRef Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178–85.PubMedCrossRef
96.
Zurück zum Zitat Chuang P, Gibney EM, Chan L, Ho PM, Parikh CR. Predictors of cardiovascular events and associated mortality within two years of kidney transplantation. Transplant Proc. 2004;36(5):1387–91.PubMedCrossRef Chuang P, Gibney EM, Chan L, Ho PM, Parikh CR. Predictors of cardiovascular events and associated mortality within two years of kidney transplantation. Transplant Proc. 2004;36(5):1387–91.PubMedCrossRef
97.
Zurück zum Zitat Fernandez-Fresnedo G, Escallada R, de Francisco ALM, et al. Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc. 2003;35(2):700.PubMedCrossRef Fernandez-Fresnedo G, Escallada R, de Francisco ALM, et al. Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc. 2003;35(2):700.PubMedCrossRef
98.
Zurück zum Zitat Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation. 1998;65(3):380–4.PubMedCrossRef Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation. 1998;65(3):380–4.PubMedCrossRef
99.
Zurück zum Zitat Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005;19(3):291–8.PubMedCrossRef Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005;19(3):291–8.PubMedCrossRef
100.
Zurück zum Zitat Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. Jan 2003;26 Suppl 1:S5–20. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. Jan 2003;26 Suppl 1:S5–20.
101.
Zurück zum Zitat Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53(3):298–304.PubMedCrossRef Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53(3):298–304.PubMedCrossRef
102.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.PubMedCrossRef Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.PubMedCrossRef
103.
Zurück zum Zitat Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta–analysis of controlled clinical trials. JAMA. 2001;286(10):1218–27.PubMedCrossRef Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta–analysis of controlled clinical trials. JAMA. 2001;286(10):1218–27.PubMedCrossRef
104.
Zurück zum Zitat Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64(2):603–9.PubMedCrossRef Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64(2):603–9.PubMedCrossRef
105.
Zurück zum Zitat Oliveras A, Roquer J, Puig JM, et al. Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. Clin Transplant. 2003;17(1):1–8.PubMedCrossRef Oliveras A, Roquer J, Puig JM, et al. Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. Clin Transplant. 2003;17(1):1–8.PubMedCrossRef
106.
Zurück zum Zitat Abedini S, Holme I, Fellstrom B, et al. Cerebrovascular events in renal transplant recipients. Transplantation. 2009;87(1):112–7.PubMedCrossRef Abedini S, Holme I, Fellstrom B, et al. Cerebrovascular events in renal transplant recipients. Transplantation. 2009;87(1):112–7.PubMedCrossRef
107.
Zurück zum Zitat Khella S, Bleicher MB. Stroke and its prevention in chronic kidney disease. Clin J Am Soc Nephrol. 2007;2(6):1343–51.PubMedCrossRef Khella S, Bleicher MB. Stroke and its prevention in chronic kidney disease. Clin J Am Soc Nephrol. 2007;2(6):1343–51.PubMedCrossRef
108.
Zurück zum Zitat Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation. 2006;81(8):1112–8.PubMedCrossRef Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation. 2006;81(8):1112–8.PubMedCrossRef
109.
Zurück zum Zitat Vanrenterghem Y. Anaemia after renal transplantation. Nephrology Dialysis Transplantation. 2004;19:54–8.CrossRef Vanrenterghem Y. Anaemia after renal transplantation. Nephrology Dialysis Transplantation. 2004;19:54–8.CrossRef
110.
Zurück zum Zitat Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol. 2003;14(2):462–8.PubMedCrossRef Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol. 2003;14(2):462–8.PubMedCrossRef
111.
Zurück zum Zitat Winkelmayer WC, Chandraker A. Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S49–55.PubMedCrossRef Winkelmayer WC, Chandraker A. Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S49–55.PubMedCrossRef
112.
Zurück zum Zitat Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant. 2003;3(7):835–45.PubMedCrossRef Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant. 2003;3(7):835–45.PubMedCrossRef
113.
Zurück zum Zitat Lorenz M, Kletzmayr J, Perschl A, Furrer A, Horl WH, Sunder-Plassmann G. Anemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol. 2002;13(3):794–7.PubMed Lorenz M, Kletzmayr J, Perschl A, Furrer A, Horl WH, Sunder-Plassmann G. Anemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol. 2002;13(3):794–7.PubMed
114.
Zurück zum Zitat Afzali B, Al-Khoury S, Shah N, Mikhail A, Covic A, Goldsmith D. Anemia after renal transplantation. Am J Kidney Dis. 2006;48(4):519–36.PubMedCrossRef Afzali B, Al-Khoury S, Shah N, Mikhail A, Covic A, Goldsmith D. Anemia after renal transplantation. Am J Kidney Dis. 2006;48(4):519–36.PubMedCrossRef
115.
Zurück zum Zitat Pamidi S, Friedman K, Kampalath B, Eshoa C, Hariharan S. Human parvovirus B19 infection presenting as persistent anemia in renal transplant recipients. Transplantation. 2000;69(12):2666–9.PubMedCrossRef Pamidi S, Friedman K, Kampalath B, Eshoa C, Hariharan S. Human parvovirus B19 infection presenting as persistent anemia in renal transplant recipients. Transplantation. 2000;69(12):2666–9.PubMedCrossRef
116.
Zurück zum Zitat Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol. 2000;11(10):S1–86.PubMed Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol. 2000;11(10):S1–86.PubMed
117.
Zurück zum Zitat II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. May 2006;47(5 Suppl 3):S16–85. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. May 2006;47(5 Suppl 3):S16–85.
118.
Zurück zum Zitat KDOQI. Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471–530.CrossRef KDOQI. Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471–530.CrossRef
119.
Zurück zum Zitat Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80(10):1383–91.PubMedCrossRef Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80(10):1383–91.PubMedCrossRef
120.
Zurück zum Zitat Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989;321(5):287–92.PubMedCrossRef Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989;321(5):287–92.PubMedCrossRef
121.
Zurück zum Zitat Braun WE. Modification of the treatment of gout in renal transplant recipients. Transplant Proc. 2000;32(1):199.PubMedCrossRef Braun WE. Modification of the treatment of gout in renal transplant recipients. Transplant Proc. 2000;32(1):199.PubMedCrossRef
122.
Zurück zum Zitat Stamp L, Searle M, O’Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005;65(18):2593–611.PubMedCrossRef Stamp L, Searle M, O’Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005;65(18):2593–611.PubMedCrossRef
123.
Zurück zum Zitat Dupont P, Hunt I, Goldberg L, Warrens A. Colchicine myoneuropathy in a renal transplant patient. Transpl Int. 2002;15(7):374–6.PubMedCrossRef Dupont P, Hunt I, Goldberg L, Warrens A. Colchicine myoneuropathy in a renal transplant patient. Transpl Int. 2002;15(7):374–6.PubMedCrossRef
124.
Zurück zum Zitat Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA. Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562–8.PubMedCrossRef Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA. Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562–8.PubMedCrossRef
125.
Zurück zum Zitat Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993;20(1):111–3.PubMed Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993;20(1):111–3.PubMed
126.
Zurück zum Zitat Rosenthal AK, Ryan LM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am. 1995;21(1):151–61.PubMed Rosenthal AK, Ryan LM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am. 1995;21(1):151–61.PubMed
127.
Zurück zum Zitat Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. Sep-Oct. 2007;20(5):391–5.CrossRef Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. Sep-Oct. 2007;20(5):391–5.CrossRef
128.
Zurück zum Zitat Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation. 1996;61(11):1661–2.PubMedCrossRef Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation. 1996;61(11):1661–2.PubMedCrossRef
129.
Zurück zum Zitat Arapaslan B, Soykan A, Soykan C, Kumbasar H. Cross-sectional assessment of psychiatric disorders in renal transplantation patients in Turkey: a preliminary study. Transplant Proc. 2004;36(5):1419–21.PubMedCrossRef Arapaslan B, Soykan A, Soykan C, Kumbasar H. Cross-sectional assessment of psychiatric disorders in renal transplantation patients in Turkey: a preliminary study. Transplant Proc. 2004;36(5):1419–21.PubMedCrossRef
130.
Zurück zum Zitat Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant. 2004;19(12):3144–9.PubMedCrossRef Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant. 2004;19(12):3144–9.PubMedCrossRef
131.
Zurück zum Zitat Dobbels F, Skeans MA, Snyder JJ, Tuomari AV, Maclean JR, Kasiske BL. Depressive disorder in renal transplantation: an analysis of Medicare claims. Am J Kidney Dis. 2008;51(5):819–28.PubMedCrossRef Dobbels F, Skeans MA, Snyder JJ, Tuomari AV, Maclean JR, Kasiske BL. Depressive disorder in renal transplantation: an analysis of Medicare claims. Am J Kidney Dis. 2008;51(5):819–28.PubMedCrossRef
132.
Zurück zum Zitat Cukor D, Rosenthal DS, Jindal RM, Brown CD, Kimmel PL. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int. 2009. Cukor D, Rosenthal DS, Jindal RM, Brown CD, Kimmel PL. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int. 2009.
133.
Zurück zum Zitat Liston HL, Markowitz JS, Hunt N, DeVane CL, Boulton DW, Ashcraft E. Lack of citalopram effect on the pharmacokinetics of cyclosporine. Psychosomatics. Jul-Aug. 2001;42(4):370–2.CrossRef Liston HL, Markowitz JS, Hunt N, DeVane CL, Boulton DW, Ashcraft E. Lack of citalopram effect on the pharmacokinetics of cyclosporine. Psychosomatics. Jul-Aug. 2001;42(4):370–2.CrossRef
134.
Zurück zum Zitat Baines LS, Joseph JT, Jindal RM. Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants. Kidney Int. 2004;65(5):1937–42.PubMedCrossRef Baines LS, Joseph JT, Jindal RM. Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants. Kidney Int. 2004;65(5):1937–42.PubMedCrossRef
135.
Zurück zum Zitat Kunzendorf U, Kramer BK, Arns W, et al. Bone disease after renal transplantation. Nephrol Dial Transplant. 2008;23(2):450–8.PubMedCrossRef Kunzendorf U, Kramer BK, Arns W, et al. Bone disease after renal transplantation. Nephrol Dial Transplant. 2008;23(2):450–8.PubMedCrossRef
136.
Zurück zum Zitat Patel S, Kwan JT, McCloskey E, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res. 2001;16(10):1863–70.PubMedCrossRef Patel S, Kwan JT, McCloskey E, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res. 2001;16(10):1863–70.PubMedCrossRef
137.
Zurück zum Zitat Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994;58(8):912–5.PubMedCrossRef Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994;58(8):912–5.PubMedCrossRef
138.
Zurück zum Zitat Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E. Bone disease after renal transplantation. Clin J Am Soc Nephrol. 2006;1(6):1300–13.PubMedCrossRef Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E. Bone disease after renal transplantation. Clin J Am Soc Nephrol. 2006;1(6):1300–13.PubMedCrossRef
139.
Zurück zum Zitat K/DOQI. clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201. K/DOQI. clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201.
140.
Zurück zum Zitat Hariharan S. Recommendations for outpatient monitoring of kidney transplant recipients. Am J Kidney Dis. 2006;47(4 Suppl 2):S22–36.PubMedCrossRef Hariharan S. Recommendations for outpatient monitoring of kidney transplant recipients. Am J Kidney Dis. 2006;47(4 Suppl 2):S22–36.PubMedCrossRef
141.
Zurück zum Zitat Palmer SC, McGregor DO, Strippoli GF Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007;(3):CD005015. Palmer SC, McGregor DO, Strippoli GF Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007;(3):CD005015.
142.
Zurück zum Zitat Cruz DN, Brickel HM, Wysolmerski JJ, et al. Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant. 2002;2(1):62–7.PubMedCrossRef Cruz DN, Brickel HM, Wysolmerski JJ, et al. Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant. 2002;2(1):62–7.PubMedCrossRef
143.
Zurück zum Zitat Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation. 2003;76(10):1498–502.PubMedCrossRef Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation. 2003;76(10):1498–502.PubMedCrossRef
144.
Zurück zum Zitat Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13.PubMedCrossRef Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13.PubMedCrossRef
145.
Zurück zum Zitat Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.PubMedCrossRef Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.PubMedCrossRef
146.
Zurück zum Zitat Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression-de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007;71(12):1271–8.PubMedCrossRef Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression-de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007;71(12):1271–8.PubMedCrossRef
147.
Zurück zum Zitat Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.PubMedCrossRef Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.PubMedCrossRef
148.
Zurück zum Zitat Serraino D, Piselli P, Busnach G, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 2007;43(14):2117–23.PubMedCrossRef Serraino D, Piselli P, Busnach G, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 2007;43(14):2117–23.PubMedCrossRef
149.
Zurück zum Zitat Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol. 2004;15(6):1582–8.PubMedCrossRef Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol. 2004;15(6):1582–8.PubMedCrossRef
150.
Zurück zum Zitat Fischereder M. Cancer in patients on dialysis and after renal transplantation. Nephrol Dial Transplant. 2008;23(8):2457–60.PubMedCrossRef Fischereder M. Cancer in patients on dialysis and after renal transplantation. Nephrol Dial Transplant. 2008;23(8):2457–60.PubMedCrossRef
151.
Zurück zum Zitat Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant. 2007;22(Suppl 1):i4–i10.PubMedCrossRef Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant. 2007;22(Suppl 1):i4–i10.PubMedCrossRef
152.
Zurück zum Zitat European best practice guidelines for renal transplantation Section IV: Long-term management of the transplant recipient. IV.6.2. Cancer risk after renal transplantation. Skin cancers: prevention and treatment. Nephrol Dial Transplant. 2002;17(Suppl)4:31–6. European best practice guidelines for renal transplantation Section IV: Long-term management of the transplant recipient. IV.6.2. Cancer risk after renal transplantation. Skin cancers: prevention and treatment. Nephrol Dial Transplant. 2002;17(Suppl)4:31–6.
153.
Zurück zum Zitat Knoll G. Trends in kidney transplantation over the past decade. Drugs. 2008;68(Suppl 1):3–10.PubMedCrossRef Knoll G. Trends in kidney transplantation over the past decade. Drugs. 2008;68(Suppl 1):3–10.PubMedCrossRef
154.
Zurück zum Zitat Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601–14.PubMedCrossRef Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601–14.PubMedCrossRef
155.
Zurück zum Zitat Padiyar A, Akoum FH, Hricik DE Management of the kidney transplant recipient. Prim Care. 2008;35(3):433–450, v.PubMed Padiyar A, Akoum FH, Hricik DE Management of the kidney transplant recipient. Prim Care. 2008;35(3):433–450, v.PubMed
156.
Zurück zum Zitat Abbott KC, Swanson SJ, Richter ER, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis. 2004;44(2):353–62.PubMedCrossRef Abbott KC, Swanson SJ, Richter ER, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis. 2004;44(2):353–62.PubMedCrossRef
157.
Zurück zum Zitat Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643–54.PubMedCrossRef Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643–54.PubMedCrossRef
158.
Zurück zum Zitat Grekas D, Thanos V, Dioudis C, Alivanis P, Tourkantonis A. Treatment of urinary tract infections with ciprofloxacin after renal transplantation. Int J Clin Pharmacol Ther Toxicol. 1993;31(6):309–11.PubMed Grekas D, Thanos V, Dioudis C, Alivanis P, Tourkantonis A. Treatment of urinary tract infections with ciprofloxacin after renal transplantation. Int J Clin Pharmacol Ther Toxicol. 1993;31(6):309–11.PubMed
159.
Zurück zum Zitat de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol. 2008;4(5):252–64.PubMedCrossRef de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol. 2008;4(5):252–64.PubMedCrossRef
160.
Zurück zum Zitat Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. Nov 2004;4 Suppl 10:160–3. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. Nov 2004;4 Suppl 10:160–3.
161.
Zurück zum Zitat Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev. 2003;16(3):357–64.PubMedCrossRef Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev. 2003;16(3):357–64.PubMedCrossRef
162.
Zurück zum Zitat Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008;8(1):9–14.PubMedCrossRef Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008;8(1):9–14.PubMedCrossRef
163.
Zurück zum Zitat Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant. 2006;6(10):2409–2417.PubMedCrossRef Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant. 2006;6(10):2409–2417.PubMedCrossRef
164.
Zurück zum Zitat Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant. 2006;6(5 Pt 2):1111–31.PubMedCrossRef Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant. 2006;6(5 Pt 2):1111–31.PubMedCrossRef
165.
Zurück zum Zitat Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant. 1997;12(8):1672–9.PubMedCrossRef Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant. 1997;12(8):1672–9.PubMedCrossRef
166.
Zurück zum Zitat Rao PS, Schaubel DE, Jia X, Li S, Port FK, Saran R. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis. 2007;49(2):294–300.PubMedCrossRef Rao PS, Schaubel DE, Jia X, Li S, Port FK, Saran R. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis. 2007;49(2):294–300.PubMedCrossRef
167.
Zurück zum Zitat Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57(1):307–313.PubMedCrossRef Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57(1):307–313.PubMedCrossRef
168.
Zurück zum Zitat Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension. 2008;52(5):818–27.PubMedCrossRef Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension. 2008;52(5):818–27.PubMedCrossRef
169.
Zurück zum Zitat From the Centers for Disease Control and Prevention, Physician and other health care professional counseling of smokers to quit-United States, 1991. JAMA. Dec 1 1993;270(21):2536–7. From the Centers for Disease Control and Prevention, Physician and other health care professional counseling of smokers to quit-United States, 1991. JAMA. Dec 1 1993;270(21):2536–7.
170.
Zurück zum Zitat Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.PubMedCrossRef Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.PubMedCrossRef
171.
Zurück zum Zitat CDC. State-Specific Prevalence of Obesity Among Adults—United States, 2005. Morbidity and Mortality Weekly Report. 2006;55(36):985–8. CDC. State-Specific Prevalence of Obesity Among Adults—United States, 2005. Morbidity and Mortality Weekly Report. 2006;55(36):985–8.
172.
Zurück zum Zitat Goff DC Jr, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006;113(5):647–56.PubMedCrossRef Goff DC Jr, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006;113(5):647–56.PubMedCrossRef
174.
Zurück zum Zitat Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–95.PubMedCrossRef Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–95.PubMedCrossRef
175.
Zurück zum Zitat Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol. 2000;20(2):176–87.PubMed Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol. 2000;20(2):176–87.PubMed
176.
Zurück zum Zitat First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol. 1994;4(8 Suppl):S30–6.PubMed First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol. 1994;4(8 Suppl):S30–6.PubMed
177.
Zurück zum Zitat Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–8.PubMedCrossRef Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–8.PubMedCrossRef
178.
Zurück zum Zitat Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129–36.PubMedCrossRef Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129–36.PubMedCrossRef
179.
Zurück zum Zitat Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–1.PubMedCrossRef Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–1.PubMedCrossRef
180.
Zurück zum Zitat Chan JC, Scott R. Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545–55.PubMedCrossRef Chan JC, Scott R. Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545–55.PubMedCrossRef
181.
Zurück zum Zitat Djamali A. Can the renal transplant patient be really considered as a patient with chronic renal insufficiency? Nephrol Ther. 2008;4(Suppl 1):S36–9.PubMed Djamali A. Can the renal transplant patient be really considered as a patient with chronic renal insufficiency? Nephrol Ther. 2008;4(Suppl 1):S36–9.PubMed
182.
Zurück zum Zitat Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol. 2007;2(4):750–6.PubMedCrossRef Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol. 2007;2(4):750–6.PubMedCrossRef
183.
Zurück zum Zitat Birdwell KA, Ikizler MR, Sannella EC, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis. 2009;54(1):112–21.PubMedCrossRef Birdwell KA, Ikizler MR, Sannella EC, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis. 2009;54(1):112–21.PubMedCrossRef
184.
Zurück zum Zitat Sanchez-Fructuoso AI, Prats D, Naranjo P, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation. 2000;69(3):436–9.PubMedCrossRef Sanchez-Fructuoso AI, Prats D, Naranjo P, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation. 2000;69(3):436–9.PubMedCrossRef
185.
Zurück zum Zitat Bernardo JF, McCauley J. Drug therapy in transplant recipients: special considerations in the elderly with comorbid conditions. Drugs Aging. 2004;21(5):323–48.PubMedCrossRef Bernardo JF, McCauley J. Drug therapy in transplant recipients: special considerations in the elderly with comorbid conditions. Drugs Aging. 2004;21(5):323–48.PubMedCrossRef
186.
Zurück zum Zitat Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67(3):369–91.PubMedCrossRef Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67(3):369–91.PubMedCrossRef
187.
Zurück zum Zitat Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58.PubMedCrossRef Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58.PubMedCrossRef
188.
Zurück zum Zitat Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging. 2009;26(9):715–37.PubMedCrossRef Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging. 2009;26(9):715–37.PubMedCrossRef
Metadaten
Titel
Primary Care of the Renal Transplant Patient
verfasst von
Gaurav Gupta, MD
Mark L. Unruh, MD
Thomas D. Nolin, PharmD, PhD
Peggy B. Hasley, MD
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Journal of General Internal Medicine / Ausgabe 7/2010
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-010-1354-5

Weitere Artikel der Ausgabe 7/2010

Journal of General Internal Medicine 7/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.